GV20 Therapeutics Reports Phase 1 Data On GV20-0251 At ESMO
16 Sep 2024 //
PR NEWSWIRE
GV20 Therapeutics To Present GV20-0251 Clinical Data At ESMO 2024
21 Aug 2024 //
PR NEWSWIRE
IGSF8 Immune Checkpoint Discovered, Cancer Target
24 Apr 2024 //
PR NEWSWIRE
GV20 Partners To Evaluate GV20-0251 + Keytruda Combination
18 Apr 2024 //
PR NEWSWIRE
GV20 Presents Data on GV20-0251 for Solid Tumors Targeting IGSF8 at AACR
08 Apr 2024 //
PR NEWSWIRE